Stay updated on Efficacy of Rifaximin with NAC in IBS-D Clinical Trial
Sign up to get notified when there's something new on the Efficacy of Rifaximin with NAC in IBS-D Clinical Trial page.

Latest updates to the Efficacy of Rifaximin with NAC in IBS-D Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedA new Locations section has been added, listing California as a study site (Los Angeles, CA). The page's references to California Locations and the HHS Vulnerability Disclosure link were removed in revision 3.3.3.SummaryDifference0.2%

- Check51 days agoChange DetectedThe Publications section now states that entries are automatically filled from PubMed and may not all pertain to the study. The revision tag was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check58 days agoChange DetectedThe government funding status notice was removed from the page. The study details content and layout remain unchanged.SummaryDifference0.3%

- Check73 days agoChange DetectedNo significant changes detected; the study record details, including title, design, eligibility criteria, interventions, outcomes, and locations, appear unchanged between the screenshots.SummaryDifference0.4%

- Check102 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference2%

Stay in the know with updates to Efficacy of Rifaximin with NAC in IBS-D Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of Rifaximin with NAC in IBS-D Clinical Trial page.